Market revenue in 2023 | USD 97,068.5 million |
Market revenue in 2030 | USD 207,213.6 million |
Growth rate | 11.4% (CAGR from 2023 to 2030) |
Largest segment | Conventional drugs (small molecules) |
Fastest growing segment | Biologics & Biosimilars (Large Molecules) |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biologics & Biosimilars (Large Molecules), Conventional Drugs (Small Molecules) |
Key market players worldwide | Roche Holding AG ADR, Novartis AG ADR, GlaxoSmithKline, Pfizer Inc, Merck & Co Inc, AstraZeneca PLC, Johnson & Johnson, Sanofi SA, Eli Lilly and Co, AbbVie Inc, Thermo Fisher Scientific Inc, Wuxi AppTec Co Ltd, Samsung BioLogics, FUJIFILM Holdings Corp, Lonza Group Ltd, Catalent Inc, Jubilant Pharmova |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical manufacturing market will help companies and investors design strategic landscapes.
Conventional drugs (small molecules) was the largest segment with a revenue share of 63.48% in 2023. Horizon Databook has segmented the Asia Pacific pharmaceutical manufacturing market based on biologics & biosimilars (large molecules), conventional drugs (small molecules) covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific consists of a blend of developing and developed economies. Increasing healthcare expenditure in the region is anticipated to fuel market growth. The increasing geriatric population and rising awareness of dry eye syndrome are among the major factors driving the market in this region.
Asia Pacific’s pharmaceutical industry has witnessed multiple developments primarily targeted toward improving productivity, conducting R&D, and utilizing novel health technologies to their highest potential.
Most governments are actively working to address recent dynamic changes in the pharmaceutical manufacturing industry caused by the COVID-19 pandemic by organizing virtual conferences. For instance, a virtual conference was held by the Parenteral Drug Association (PDA) - Asia Pacific in September 2020.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific pharmaceutical manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific pharmaceutical manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account